Stomach cancer risk after treatment for hodgkin lymphoma.

ABSTRACT:

Purpose

Treatment-related stomach cancer is an important cause of morbidity and mortality among the growing number of Hodgkin lymphoma (HL) survivors, but risks associated with specific HL treatments are unclear.

Patients and methods

We conducted an international case-control study of stomach cancer nested in a cohort of 19,882 HL survivors diagnosed from 1953 to 2003, including 89 cases and 190 matched controls. For each patient, we quantified cumulative doses of specific alkylating agents (AAs) and reconstructed radiation dose to the stomach tumor location.

Results

Stomach cancer risk increased with increasing radiation dose to the stomach (Ptrend < .001) and with increasing number of AA-containing chemotherapy cycles (Ptrend = .02). Patients who received both radia

SUBMITTER: Morton LM 

PROVIDER: S-EPMC3770865 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature